title: Efficacy and safety of long-term (>7 year) alemtuzumab therapy for refractory T-cell large granular lymphocytic leukaemia.
authors.forename: Horatiu
authors.initials: H
authors.lastname: Olteanu
authors.forename: Alexandra M
authors.initials: AM
authors.lastname: Harrington
authors.forename: Sarah
authors.initials: S
authors.lastname: Ramirez
authors.forename: Steven H
authors.initials: SH
authors.lastname: Kroft
authors.forename: Parameswaran
authors.initials: P
authors.lastname: Hari
mesh_terms: D000074323:Alemtuzumab; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D054066:Leukemia, Large Granular Lymphocytic / Q000188:drug therapy*; D008875:Middle Aged; D016553:Purpura, Thrombocytopenic, Idiopathic / Q000139:chemically induced
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm; D000970:Antineoplastic Agents; D000074323:Alemtuzumab